Accepted Manuscript One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular AgeRelated Macular Degeneration Cheryl A. Arcinue , Feiyan Ma , Giulio Barteselli , Lucie Sharpsten , Maria Laura Gomez , William R. Freeman PII:
S0002-9394(14)00738-7
DOI:
10.1016/j.ajo.2014.11.022
Reference:
AJOPHT 9154
To appear in:
American Journal of Ophthalmology
Received Date: 31 August 2014 Revised Date:
8 November 2014
Accepted Date: 12 November 2014
Please cite this article as: Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR, One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration, American Journal of Ophthalmology (2014), doi: 10.1016/j.ajo.2014.11.022. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
ABSTRACT
Design: Retrospective, interventional, consecutive case series.
RI PT
Purpose: To evaluate 6-month and 1-year outcomes of every 8 weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD).
Methods: Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every 4 weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept.
M AN U
SC
Results: Sixty-three eyes of 58 patients had a median of 13 (interquartile range (IQR), 7-22) previous anti Vascular Endothelial Growth Factor (anti-VEGF) injections. At 6-months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to one-year. The median maximum retinal thickness improved from 355 microns to 269 microns at 6 months (p
S0002-9394(14)00738-7
DOI:
10.1016/j.ajo.2014.11.022
Reference:
AJOPHT 9154
To appear in:
American Journal of Ophthalmology
Received Date: 31 August 2014 Revised Date:
8 November 2014
Accepted Date: 12 November 2014
Please cite this article as: Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR, One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration, American Journal of Ophthalmology (2014), doi: 10.1016/j.ajo.2014.11.022. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
ABSTRACT
Design: Retrospective, interventional, consecutive case series.
RI PT
Purpose: To evaluate 6-month and 1-year outcomes of every 8 weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD).
Methods: Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every 4 weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept.
M AN U
SC
Results: Sixty-three eyes of 58 patients had a median of 13 (interquartile range (IQR), 7-22) previous anti Vascular Endothelial Growth Factor (anti-VEGF) injections. At 6-months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to one-year. The median maximum retinal thickness improved from 355 microns to 269 microns at 6 months (p
